Overview
Palmitoylethanolamide (PEA) is a naturally occurring lipid molecule widely recognized for its ability to support the endocannabinoid system, modulate pain pathways, and help control inflammation.
Backed by strong scientific evidence, PEA is now considered a key nutraceutical ingredient for the management of occasional pain.

However, standard PEA faces certain limitations: its poor solubility and low absorption can reduce bioavailability, while a slower onset of action may limit its immediate effectiveness.

To overcome these challenges, Giellepi has developed WELLPEA^®, an innovative patent-pending formulation that acts on both central and peripheral pain pathways. By amplifying PEA’s effects through distinct yet complementary mechanisms, WELLPEA^® delivers faster and longer-lasting benefits for daily well-being.